SPECIAL NOTICE
65 -- TECHNOLOGY TRANSFER OPPORTUNITY: Microneedle Array for In Vivo Electrochemical Immunoassay and Analyte Detection.
- Notice Date
- 12/17/2008
- Notice Type
- Special Notice
- NAICS
- 334111
— Electronic Computer Manufacturing
- Contracting Office
- Department of Energy, Sandia Corp. (DOE Contractor), Sandia National Laboratories, PO Box 5800, MS: 0115, Albuquerque, New Mexico, 87185
- ZIP Code
- 87185
- Solicitation Number
- 08_317
- Response Due
- 1/24/2009
- Archive Date
- 1/26/2009
- Point of Contact
- Daisy Segura, Fax: (505) 844-8011
- E-Mail Address
-
dsegura@sandia.gov
- Small Business Set-Aside
- N/A
- Description
- Sandia National Laboratories, the lead research and development laboratory for the Department of Energy’s physical security needs, is seeking one or more business partners in the medical diagnostics field, including but not limited to glucose detection, to develop Sandia’s microneedle technology. Sandia is seeking a company or companies to commercially license the technology described in this posting, and expects the successful company(ies) to engage in the creation of a Cooperative Research and Development Agreement (CRADA) with Sandia to further develop the technology. Commercial licensees will have the opportunity to obtain a license to the intellectual properties for reasonable compensation. It is expected that the company(ies) that works with Sandia to develop the microneedle technology will promptly incorporate it into a commercial product. Potential partners must provide Sandia information describing their ability to research, design, develop, manufacture, distribute, market, and service fully functional diagnostics systems. The subject technology is a platform of multiple microneedles, capable of painlessly passing into a patient’s skin and accessing interstitial fluid. In one embodiment, the microneedles are configured as individually addressable microelectrodes and various analytes are detected in vivo via electrochemical methods, allowing analytes possessing redox behaviors to be easily detected in real-time without pain to the patient. In another embodiment, various analytes are chemically bound to the microneedles, removed from the patient, and detected via methods such as optical and chemical techniques. To date, Sandia has demonstrated glucose detection with this technology. To express interest in this opportunity, please respond by mail or fax to Daisy Segura by 23 January 2009 at: Sandia National Laboratories, MS 0115, P.O. Box 5800, Albuquerque New Mexico 87185-0115, Fax (505) 844-8011, E-mail: dsegura@sandia.gov. Please indicate the date and title of the FBO notice. Include company and contact information, as well as a description of how your company meets Sandia’s criteria and could best contribute to the formation of a CRADA partnership or license and the subsequent commercialization of this technology. Sandia is a multiprogram laboratory operated by Sandia Corporation, a Lockheed Martin Company, for the United States Department of Energy’s National Nuclear Security Administration under Contract DE-AC04-94AL85000.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=dde232f7f8dd5719a9d15dc3c475f669&tab=core&_cview=1)
- Record
- SN01720622-W 20081219/081217220437-dde232f7f8dd5719a9d15dc3c475f669 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |